ATR News & Events

The company states: "AptarGroup announced that its Unidose Powder Nasal Spray System is being utilized in ENA Respiratory's Phase II clinical study of INNA 051, an investigational nasal spray being evaluated for its potential to help protect against symptomatic viral respiratory infections. This collaboration reflects the growing role of intranasal delivery technologies in supporting the development of novel, non-vaccine approaches to respiratory disease prevention."

AptarGroup announced that Gael Touya, most recently Aptar Pharma president, has been appointed president and CEO, effective September 1. He will succeed Stephan Tanda, who has served as president and CEO since 2017. Stephan is expected to continue to work closely with Touya and the board as an advisor through the end of the year. Tanda intends to retire from Aptar's board by the end of 2026 and the board will appoint Gael as a director on September 1.